News
AVCNF
0.097
+3.97%
0.004
Weekly Report: what happened at AVCNF last week (0803-0807)?
Weekly Report · 44m ago
Weekly Report: what happened at AVCNF last week (0727-0731)?
Weekly Report · 08/03 09:37
Weekly Report: what happened at AVCNF last week (0720-0724)?
Weekly Report · 07/27 09:39
Weekly Report: what happened at AVCNF last week (0713-0717)?
Weekly Report · 07/20 09:37
Stocks in play: Avicanna Inc.
Barchart · 07/16 08:36
Avicanna Introduces QUIX™ Rapid-Onset Medical Cannabis Portfolio
Barchart · 07/16 06:30
Weekly Report: what happened at AVCNF last week (0706-0710)?
Weekly Report · 07/13 09:38
Weekly Report: what happened at AVCNF last week (0629-0703)?
Weekly Report · 07/06 09:40
Avicanna strengthens leadership; promotes Nick Hilborn to CFO role
Seeking Alpha · 06/30 21:56
Weekly Report: what happened at AVCNF last week (0622-0626)?
Weekly Report · 06/29 09:37
Weekly Report: what happened at AVCNF last week (0615-0619)?
Weekly Report · 06/22 09:42
Weekly Report: what happened at AVCNF last week (0608-0612)?
Weekly Report · 06/15 09:43
Weekly Report: what happened at AVCNF last week (0601-0605)?
Weekly Report · 06/08 09:40
Weekly Report: what happened at AVCNF last week (0525-0529)?
Weekly Report · 06/01 09:43
Weekly Report: what happened at AVCNF last week (0518-0522)?
Weekly Report · 05/25 09:44
Weekly Report: what happened at AVCNF last week (0511-0515)?
Weekly Report · 05/18 09:44
Avicanna Inc. reports Q1 results
Seeking Alpha · 05/15 13:03
Weekly Report: what happened at AVCNF last week (0504-0508)?
Weekly Report · 05/11 09:42
Weekly Report: what happened at AVCNF last week (0427-0501)?
Weekly Report · 05/04 09:41
Avicanna announces McCormack tendered her resignation as member of board
TipRanks · 05/03 18:00
More
Webull provides a variety of real-time AVCNF stock news. You can receive the latest news about Avicanna through multiple platforms. This information may help you make smarter investment decisions.
About AVCNF
Avicanna Inc. is a commercial-stage international biopharmaceutical company. It focuses on the advancement and commercialization of cannabinoid-based products and formulations for the global medical and pharmaceutical market segments. Its products and services are grouped into four main categories, such as medical cannabis products; MyMedi.ca medical cannabis platform; pharmaceutical pipeline; and active pharmaceutical ingredients. The formulary of proprietary medical cannabis products is marketed under the RHO Phyto brand and offers a range of scientifically driven formulations in a variety of products, including oral, sublingual, topical, and transdermal deliveries with varying ratios of cannabinoids. MyMedi.ca offers a diverse portfolio of products and bilingual pharmacist-led patient support programs. It has developed a pipeline of proprietary, indication-specific cannabinoid-based candidates that are in various stages of clinical development. Trunerox is its oral formulation.